Part I . Introduction.- 1. HCT: Historical Perspective.- 2. The EBMT: History, Present, and Future.- 3. Registries - a bridge between donor and recipient.- 4. The HCT Unit.- 5. JACIE Accreditation of HCT Programs.- 6. Statistical Methods in HCT and Cellular Therapies.- Part II . Biological Aspects.- 7. Biological Properties Of Hematopoietic Stem Cells: Scientific Basis For Hematopoietic Cell Transplantation.- 8. Biological Properties of Cells Other Than HSCs.- 9. Histocompatibility.- 10. Clinical and biological concepts for mastering immune reconstitution after hematopoietic cell transplantation: towards practical guidelines and greater harmonization.- Part III . Methodology and Clinical Aspects.- 11. Evaluation and Counseling of Candidates.- 12. Donor Selection for Adults and Pediatrics.- 13. Conditioning.- 14. Selection of stem cell source.- 15. Bone Marrow Harvesting for HCT.- 16. Mobilization and Collection of HSC.- 17. Mobilization and Collection of HSC in Children.- 18. Procurement and Management of Cord Blood Unit for allogeneic transplantation.- 19. Graft Manipulation.- 20. Processing, Cryopreserving and Controlling the Quality of HSC.- 21. Documentation of Engraftment and Chimerism After HCT.- 22. Short- and Long-Term Controls After HCT.- Part IV . General Management of the Patient.- 23. Vascular Access.- 24. Transfusion Support.- 25. Nutritional Support.- 26. GVHD Prophylaxis.- 27. Infection Control and Isolation Procedures.- 28. General Management of the Patient: Specific Aspects of Infectious Disease Supportive Care in Children.- 29. Vaccinations.- 30. Psychological Morbidity and Care.- 31. Clinically Relevant Drug Interactions in HCT.- 32. The Roles of the HCT Nurse.- 33. Ethical Issues in HCT.- 34. Quality of Life Assessment After HCT for Pediatric and Adults.- Part V. HCT Complications and Management.- 35. Neutropenic Fever.- 36. Bacterial Infections.- 37. Invasive fungal diseases.- 38. Viral Infections.- 39. Other Life-Threatening Infections.- 40. Bleeding and Thrombotic Complications.- 41. Graft Failure.- 42. Early complications of endothelial origin.- 43. Acute Graft-Versus-Host Disease.- 44. Chronic Graft-Versus-Host Disease.- 45. Post-transplant lymphoproliferative syndromes.- 46. Iron Overload.- 47. Secondary Neoplasia (Other than PTLPS).- Part VI . Specific Organ Complications.- 48. Ocular and Oral Complications .- 49. Hepatic complications.- 50. Gastrointestinal Complications.- 51. Haemorrhagic Cystitis and Renal Dysfunction.- 52. Noninfectious Pulmonary Complications.- 53. Neurological Complications.- 54. Skin, Hair and Musculoskeletal Complications.- 55. Cardiovascular Diseases and Metabolic Syndrome.- 56. Endocrine Disorders, Fertility and Sexual Health.- Part VII . Prevention and Management of Relapse.- 57. Monitoring Measurable Residual Disease in ALL and AML.- 58. Prevention and Treatment of Relapse by Drugs.- 59. Delayed transfer of immune cells, or the art of donor lymphocyte infusion (DLI) 2.0.- 60. Cellular Therapy with Engineered T Cells, Efficacy and Side Effects: Gene Editing/Gene Therapy.- 61. Mechanisms of Immune Resistance.- 62. Regulatory Aspects Of Atmp Versus Minimally Manipulated Immune Cells.- Part VIII . Specific Modalities of HCT and Management.- 63. At Home HCT.- 64. Role Of Umbilical Cord Blood Transplantation.- 65. Haploidentical HCT.- 66. Photopheresis in Adults and Pediatrics.- 67. Overweight and obese patients.- 68. HCT in Elderly Patients.- 69. Feasibility and Experiences of HCT in Resource-constrained Settings.- Part IX . Indications and Results.- 70. AML in adults.- 71. Acute Myeloid Leukemia in Children.- 72. Acute Lymphoblastic Leukemia in Adults.- 73. Acute Lymphoblastic Leukemia in Children and Adolescents.- 74. Myelodysplastic Neoplasms/Syndromes (MDS).- 75. Allogeneic hematopoietic cell transplantation in pediatric MDS including refractory cytopenia of childhood and in juvenile myelomonocytic leukemia .- 76. Myelodysplastic/Myeloproliferative Neoplasms.- 77. Myeloproliferative Neoplasms.- 78. Acquired bone marrow failure: Severe Aplastic Anemia and Paroxysmal nocturnal hemoglobinuria.- 79. Fanconi Anemia and Other Hereditary Bone Marrow Failure Syndromes.- 80. Hemoglobinopathies (Sickle Cell Disease and Thalassemia).- 81. Multiple Myeloma.- 82. Systemic Light Chain Amyloidosis.- 83. Poems Syndrome And Disease Produced By Other Monoclonal IGS.- 84. Indolent Lymphoma.- 85. CHRONIC LYMPHOCYTIC LEUKEMIA.- 86. Large B-Cell Lymphoma.- 87. Mantle Cell Lymphoma.- 88. Other B- and T-Aggressive Lymphomas & Lymphomas Associated with HIV.- 89. Classical Hodgkin's Lymphoma.- 90. Inborn errors of immunity.- 91. Inborn Errors of Metabolism and Osteopetrosis.- 92. Autoimmune Disease.- 93. CART cells & other cell therapies (ie MSC, Tregs) in autoimmune diseases.- 94. Solid Tumours.